Bringing New Cancer Drugs to Market with Founder & CEO, Lewis Bender

<p>In this episode, our guest is Lewis Bender, Chairman, and CEO, of Intensity Therapeutics’ Founder which is a late-stage clinical biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while training the patient’s immune system to fight the cancer.  The Company’s lead product candidate, INT230-6, is currently in human clinical studies to treat refractory solid tumors.</p><p><br>Talking points:<br><strong>Milestone Achievement: </strong><em>"Congratulations on dosing the first patient in the INVINCIBLE-4 Phase 2 clinical trial for triple-negative breast cancer. Can you walk us through the significance of this milestone and what it means for the future of Intensity Therapeutics?"</em></p><p><br></p><p><strong>Innovative Approach of INT230-6: </strong><em>"Intensity Therapeutics focuses on developing cancer treatments that not on...